Meta introduces prescription Ray-Ban smart glasses in an effort to appeal to billions of eyewear consumers.

      Meta is set to introduce two new Ray-Ban smart glasses models aimed at prescription users, according to a Bloomberg report released on Thursday. The models, which are codenamed Scriber and Blazer, were initially identified in filings with the Federal Communications Commission and may be available to consumers as soon as next week. These models do not signify a new generation of hardware, but rather a potentially significant distribution strategy.

      Prescription glasses make up approximately 69 percent of the $223 billion global eyewear market. In 2025, Meta sold over seven million Ray-Ban and Oakley AI frames—an impressive number for a product category that scarcely existed three years prior—yet it pales in comparison to the estimated 1.5 billion individuals worldwide who wear corrective lenses. The new models represent Meta's clearest effort to transition smart glasses from the realm of consumer electronics into mainstream optical retail, a sector characterized by a larger customer base, margins, and overall scale.

      What the new models are, and what they are not

      Scriber and Blazer are AI glasses without a display, sharing capabilities with the existing Ray-Ban Meta line, which includes a camera, microphone, speakers, and Meta AI integration, but lacks a screen. Blazer will be available in standard and large sizes, while Scriber appears to be a single-size option. Both models will support Wi-Fi 6 UNII-4 band, an upgrade from current models, and will come with charging cases.

      This distinction is important because Meta already offers a model equipped with a display. The Ray-Ban Meta Display, which debuted at Connect 2025, features a full-color heads-up display, a 12-megapixel camera with a 3x zoom, and syncs with a neural wristband that interprets muscle signals to control the interface. It is priced at $799. Meanwhile, Orion, Meta’s advanced augmented reality prototype with holographic displays, remains a research project without a consumer launch date.

      Scriber and Blazer are positioned beneath both in the product hierarchy. Their goal is not to display Meta's most cutting-edge technology but to incorporate Meta AI into frames that consumers already need to purchase. The reasoning behind this initiative is clear: if someone requires prescription lenses and is prepared to spend several hundred dollars at an optician, the additional expense of adding smart capabilities to those lenses becomes much more manageable. Mark Zuckerberg clarified this strategic reasoning during a recent earnings call, stating that “billions of people wear glasses or contacts for vision correction” and suggesting it is “difficult to envision a future where most glasses don’t incorporate AI.”

      The EssilorLuxottica question

      The shift towards prescription glasses directly intersects with the most complex relationship within Meta’s hardware business. EssilorLuxottica, the Franco-Italian conglomerate that owns Ray-Ban, Oakley, LensCrafters, and Sunglass Hut, manufactures all of Meta’s smart glasses and controls the retail optical channels through which the new models will be sold. While the partnership has yielded positive results, it has also created friction.

      Reports from Bloomberg in February indicated that the two companies are addressing disagreements regarding pricing and strategy. EssilorLuxottica’s adjusted gross margin dropped by 2.6 percentage points in 2025 to 60.9 percent, partly due to the increased component costs associated with smart glasses compared to traditional frames. Meta sought to offer Black Friday promotions in 2023; however, EssilorLuxottica, which carefully maintains its luxury status, declined the proposal. This tension is rooted in contrasting objectives: Meta aims to maximize adoption and integrate users into its AI ecosystem, while EssilorLuxottica wishes to preserve margins on a product line that is compromising them.

      Introducing prescription models could alleviate some of that tension. Prescription lenses typically command higher retail prices and better margins than non-prescription sunglasses. The additional costs associated with lens coatings, custom grinding, and fitting appointments all contribute to increased revenue along the value chain. Should smart glasses successfully enter the prescription market on a large scale, it could enhance the economics for EssilorLuxottica while also boosting volume for Meta. It has been reported that the companies are contemplating increasing their combined production target to 20 million units annually, up from an estimated capacity of 10 million by the close of 2026.

      The risks in the optician’s chair

      However, selling smart glasses through optical retail presents complications that consumer electronics channels do not face. Opticians are skilled in fitting lenses but are not accustomed to explaining AI assistants, camera privacy options, or software updates. The customer experience at a LensCrafters is fundamentally different from that at a Meta Store or Apple Store, and the training, product support, and returns handling required for a connected device are significantly more complex than for a standard pair of Wayfarers.

      Additionally, legal risks exist. In January 2026, Solos Technology filed a patent infringement lawsuit against Meta and EssilorLuxottica,